The landscape of diabetes care is undergoing a significant evolution with the introduction of rapidly disintegrating GLP-1 medications. These groundbreaking formulations, designed to quickly dissolve under the sublingually, offer the potential for faster absorption and a lower need for scheduled injections. This approach could enhance patient stick

Viking Therapeutics has formed a mutually beneficial alliance with U.S. biopharmaceutical companies to develop and manufacture its GLP-1 drug candidate, VK2735. This marks a significant advancement in securing dependable production capabilities for these vital therapeutic agents. The agreement enables them to handle large-scale peptide manufacturin